- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 ...
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results